The Peptide Reference
The Peptide Reference
References
Reference/Mitochondrial-derived peptide (MDP)

MOTS-c

Mitochondrial-Derived Peptide · Metabolic Regulator

Animal in vivo
research use only

MOTS-c is a mitochondrial-derived peptide that operates as a mitohormone through the Folate-AICAR-AMPK pathway. Under metabolic stress, it translocates to the nucleus to bind stress-response transcription factors (NRF2, ATF1/ATF7), regulating genes involved in metabolism and cellular adaptation.

Enhanced insulin sensitivity (~30% improvement)Improved glucose metabolism and toleranceAMPK pathway activationMitochondrial function optimization
01

Overview

MOTS-c is a mitochondrial-derived peptide that operates as a mitohormone through the Folate-AICAR-AMPK pathway. Under metabolic stress, it translocates to the nucleus to bind stress-response transcription factors (NRF2, ATF1/ATF7), regulating genes involved in metabolism and cellular adaptation.

Inhibits the folate cycle leading to AMPK activation. Under metabolic stress, translocates to nucleus to bind stress-response transcription factors, regulating genes involved in metabolism, insulin sensitivity, and cellular adaptation.

Evidence profilederived from 5 references
C
Animal in vivo
Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.
02

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Metabolic3
Insulin Resistance

Improves insulin sensitivity by ~30% in animal studies through AMPK activation.

Large
Type 2 Diabetes Support

Restores metabolic function via insulin receptor sensitization.

Large
Obesity Prevention

Promotes fatty acid oxidation despite identical caloric intake.

Moderate
Anti-Aging3
Age-Related Decline Reversal

Reverses age-dependent physical decline in animal models.

Moderate
Mitochondrial Biogenesis

Enhances mitochondrial function via PGC-1α activation.

Moderate
Lifespan Extension

6.4% median lifespan extension observed in mice studies.

Moderate
Exercise Performance3
Running Performance

12-15% improvement in running performance from single dose in studies.

Small
Muscle Homeostasis

Exercise induced 11.9-fold increase in skeletal muscle MOTS-c.

Small
Recovery Support

Supports muscle recovery and adaptation to exercise.

Small
i

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only
Class
Mitochondrial-derived peptide (MDP)
Chain length
16 residues
Molecular weight
2174.6 Da
Half-life
~30 min
Typical dose
Start 5mg daily, increase to 10-15mg based on goals
Frequency
Daily for metabolic support, or 3x weekly for anti-aging
Cycle length
4-12 weeks depending on goals
Storage
Refrigerate reconstituted solution at 2-8°C, use within 14 days
03

Molecular data

Type
Mitochondrial-derived peptide (MDP)
Molecular weight
2174.6 Da
Chain length
16 residues
Half-life
30 min
Primary sequenceN → C · 16 residues
H₂N–
MMet1
RArg2
WTrp3
QGln4
EGlu5
MMet6
GGly7
YTyr8
IIle9
FPhe10
YTyr11
PPro12
RArg13
KLys14
LLeu15
RArg16
–OH
MRWQEMGYIFYPRKLR
NonpolarPolarAcidicBasic
04

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

ContextRouteAmountFrequency
Metabolic healthSubQ5-10mgOnce daily
Anti-aging protocolSubQ15mg3x weekly
Exercise performanceSubQ10-15mgPre-workout
Conservative startSubQ5mgOnce daily
05

Interactions

Metformin

Both activate AMPK; monitor for additive hypoglycemic effects.

monitor
NAD+ Precursors

Complementary mitochondrial enhancement through different pathways.

synergistic
Growth Hormone Peptides

Different mechanisms allow safe combination.

compatible
Berberine

Both are AMPK activators; monitor for additive effects.

monitor
Resveratrol

Complementary SIRT1/AMPK activation pathways.

synergistic
Diabetes Medications

May require dose adjustments to prevent hypoglycemia.

monitor
06

Quality checklist

  • White to off-white powder with uniform appearance indicating proper storage
  • Clear, colorless solution without particles after reconstitution
  • Sequence verification (MRWQEMGYIFYPRKLR) with CoA >95% purity by RP-HPLC
  • !Limited human clinical data - start conservatively
  • !WADA banned substance - not for competitive athletes
  • ×Discolored powder or solution
  • ×Cloudy solution after reconstitution
  • ×No certificate of analysis available
07

What to expect

Week 1-2AMPK pathway activation; initial glucose tolerance improvements
Week 2-4Enhanced exercise capacity; improved insulin sensitivity
Week 4-8Sustained metabolic benefits; potential body composition changes
Week 8-12Maximum mitochondrial function enhancement; metabolic flexibility
08

Safety

Commonly reported2
  • Generally well-tolerated in animal studies with minimal side effects
  • Mild injection site reactions (redness, swelling)
Stop and seek advice4
  • Severe allergic reactions or anaphylaxis
  • Recurrent hypoglycemia (<50 mg/dL)
  • Persistent severe injection site reactions
  • Unexplained weight loss >10% of baseline
Contraindications3
  • Pregnancy or breastfeeding
  • WADA prohibited substance (banned for athletic competition)
  • Limited long-term human safety data
09

FAQ

How does MOTS-c help with insulin resistance?

MOTS-c activates AMPK, a cellular energy sensor that improves insulin sensitivity by approximately 30% in animal studies. It works through the Folate-AICAR-AMPK pathway, enhancing glucose uptake in muscle tissue. This addresses metabolic dysfunction at the mitochondrial level.

Does MOTS-c work for weight loss?

Indirectly. MOTS-c promotes fatty acid oxidation despite identical caloric intake, improving metabolic flexibility. Combined with exercise and diet, it enhances the body's ability to burn fat for fuel. It's not a direct weight-loss peptide like GLP-1 agonists, but supports metabolic health.

Can MOTS-c extend lifespan in humans?

Unknown in humans. Animal studies show 6.4% median lifespan extension in mice. MOTS-c clearly supports healthspan and metabolic optimization, but human longevity data doesn't exist. It's a longevity-supporting compound, not a proven life-extension drug.

Should I take MOTS-c before or after exercise?

Morning before exercise is optimal. MOTS-c activates AMPK within 30 minutes, enhancing exercise performance by 12-15% in studies. Post-workout benefits are also seen for recovery. However, pre-exercise timing maximizes the performance enhancement during the workout itself.

10

References

  1. 1
    The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
    Lee, C., et al. · Cell Metabolism · 2015

    Landmark discovery paper identifying MOTS-c as a 16-amino-acid peptide encoded by mitochondrial DNA. Prevented age-dependent and high-fat-diet-induced insulin resistance and obesity in mice via AMPK activation in skeletal muscle.

  2. 2
    The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress
    Kim, S.J., et al. · Cell Metabolism · 2018

    MOTS-c rapidly translocates to the nucleus within 30 minutes under metabolic stress in an AMPK-dependent manner, where it interacts with stress-responsive transcription factors including NRF2 and ATF7 to regulate nuclear gene expression.

  3. 3
    MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis
    Reynolds, J.C., et al. · Nature Communications · 2021

    Exercise induced an 11.9-fold increase in skeletal muscle MOTS-c. MOTS-c enhanced physical performance across age groups and improved muscle homeostasis in aging mice.

  4. 4
    MOTS-c Increases in Skeletal Muscle Following Long-Term Physical Activity and Improves Acute Exercise Performance After a Single Dose
    Hyatt, J.K. · Physiological Reports · 2022

    4-8 weeks of voluntary running increased MOTS-c protein expression ~1.5-5-fold in rodent skeletal muscles, sustained for 4-6 weeks of detraining. Single dose improved acute exercise performance.

  5. 5
    The Mitochondrial-Derived Peptide MOTS-c Relieves Hyperglycemia and Insulin Resistance in Gestational Diabetes Mellitus
    Yin, Y., et al. · Pharmacological Research · 2022

    MOTS-c significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and reduced birth weight and offspring death in a gestational diabetes mouse model.

For research use only. Nothing on this page is medical advice, and no number here is a recommendation to dose.